AmpliPhis novel bacteriophage therapy demonstrates comparable efficacy to vancomycin in S.

AmpliPhi’s novel bacteriophage therapy demonstrates comparable efficacy to vancomycin in S. Aureus lung contamination model Results presented in the Joint Interscience Meeting of Antimicrobial Agents and Chemotherapy and International Congress of Chemotherapy and Disease 2015 conference AmpliPhi Biosciences Corporation , a worldwide leader in the development of bacteriophage-based antibacterial therapies to take care of drug-resistant attacks, today announced experimental outcomes highlighting that it is prototype bacteriophage cocktail demonstrated comparable efficacy to vancomycin in reduction of Staphylococcus aureus in a murine lung infection model. Data from this scholarly study, performed in collaboration with the Hearts Consulting Group and the University of North Texas Wellness Science Center, were provided at the joint Interscience Conference of Antimicrobial Brokers and Chemotherapy and International Congress of Chemotherapy and Illness 2015 meeting, from September 17-21 taking place in San Diego http://priligynorge.com .

Other entries from category "slimming":

Tag Cloud